Severity
Moderate
FDA Drug recall · Reported October 30, 2019
GMP Deviations: potential glass contamination
Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center recalled PF-Fentanyl Citrate 2 mcg/mL* & Ropivacaine HCl 0.1% in 0.9% Sodium Chloride Injection-20… - a moderate-severity action.
PF-Fentanyl Citrate 2 mcg/mL* & Ropivacaine HCl 0.1% in 0.9% Sodium Chloride Injection-20… was recalled by Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center in October 30, 2019. Reason: GMP Deviations: potential glass contamination. Check the official notice for the remedy. Verify recall #D-0149-2020 with the FDA Drug before acting.
The recall
Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center issued this moderate-severity FDA Drug recall-GMP Deviations: potential glass contamination.
Sourced from official FDA Drug enforcement records. Verify recall #D-0149-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0149-2020) was formally reported on October 30, 2019, with the manufacturer initiating the action on October 9, 2019. It is classified under Moderate severity (Class II), with a current status of Terminated. Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center is listed as the recalling firm, operating out of West Columbia, SC. Federal records list the affected scope as 615 bags.
The documented reason for this recall is: GMP Deviations: potential glass contamination Distribution data in the federal record shows the product reached: Nationwide.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
615 bags
Related Recalls
6
5 from same agency
PF-Fentanyl Citrate 2 mcg/mL* & Ropivacaine HCl 0.1% in 0.9% Sodium Chloride Injection-200 mL Total Dose: (400 mcg/200 mg)/200 mL, Rx Only Nephron 503B Outsourcing Facility 4500 12th St. Extension West Columbia, SC 29172 NDC: 69374-526-20
GMP Deviations: potential glass contamination
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0149-2020 |
| Date reported | October 30, 2019 |
| Date initiated | October 9, 2019 |
| Recalling firm | Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center |
| Firm location | West Columbia, SC |
| Affected scope | 615 bags |
| Distribution | Nationwide. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported October 30, 2019. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.